Vistagen presents new fasedienol (ph94b) research at 2023 anxiety and depression association of america conference

South san francisco, calif.--(business wire)--vistagen (nasdaq: vtgn), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (cns) disorders, today announced new data, presented at the 2023 anxiety and depression association of america (adaa) conference in washington, d.c.
VTGN Ratings Summary
VTGN Quant Ranking